CD1 molecules are a third category of antigen presenting molecules, distinct from the MHC class I and class II molecules. A distinguishing feature of CD1 molecules is their ability to present lipid-containing antigens. Several different types of T cells can respond to CD1, including the NK T cells, a distinct lymphocyte subset that express both T cell antigen receptors (TCRs) and NK receptors. CD1 autoreactivity by NK T cells is greatly augmented by the addition of the lipoglycan alpha galactosyl ceramide (alphaGalCer). A distinguishing feature of NK T cells is their ability to rapidly secreted large amounts of cytokines following antigen stimulation. NK T cells, and the cytokines they secreted have been implicated as important elements controlling a variety of immune responses, including the response to tumors. NK T cells also have been implicated in preventing autoimmune disease progression, particularly for diabetes in animal models as well as in patients. This application is concerned with the antigen presenting function of CD1d molecules, and in particular, how the interaction of CD1d with lipid antigens and T cell antigen receptors (TCRs) is important in determining how the cytokine output from NK T cells and their in vivo behavior We will employ site directed mutagenesis of mouse CD1.1 (mCD1), in order to define how mCD1 can stimulate autoreactive, T cells and present both lipid and peptide antigens. Finally, we will explore how these molecular interactions alter the development of diabetes in NOD mice. In summary, the experiments are designed to achieve a better understanding of how the secretion of cytokines by NK T cells is controlled. Suck knowledge could lead to novel immune therapies for cancer and autoimmune disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA052511-12
Application #
6628261
Study Section
Immunobiology Study Section (IMB)
Program Officer
Mccarthy, Susan A
Project Start
1991-04-01
Project End
2005-01-31
Budget Start
2003-02-01
Budget End
2004-01-31
Support Year
12
Fiscal Year
2003
Total Cost
$364,838
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Akbari, Omid; Faul, John L; Hoyte, Elisabeth G et al. (2006) CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 354:1117-29
Geissmann, Frederic; Cameron, Thomas O; Sidobre, Stephane et al. (2005) Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 3:e113
Godfrey, Dale I; Kronenberg, Mitchell (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379-88
Stenstrom, Martin; Skold, Markus; Ericsson, Anna et al. (2004) Surface receptors identify mouse NK1.1+ T cell subsets distinguished by function and T cell receptor type. Eur J Immunol 34:56-65
Akbari, Omid; Stock, Philippe; Meyer, Everett et al. (2003) Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 9:582-8
Hammond, Kirsten J L; Kronenberg, Mitchell (2003) Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol 15:683-9
Skold, Markus; Stenstrom, Martin; Sidobre, Stephane et al. (2003) MHC-dependent and -independent modulation of endogenous Ly49 receptors on NK1.1+ T lymphocytes directed by T-cell receptor type. Immunology 110:313-21
Matsuda, Jennifer L; Gapin, Laurent; Baron, Jody L et al. (2003) Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A 100:8395-400
Crowe, Nadine Y; Uldrich, Adam P; Kyparissoudis, Konstantinos et al. (2003) Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 171:4020-7
Elewaut, Dirk; Shaikh, Raziya B; Hammond, Kirsten J L et al. (2003) NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J Exp Med 197:1623-33

Showing the most recent 10 out of 28 publications